Basilea Pharmaceutica
63
5
5
49
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
11.1%
7 terminated/withdrawn out of 63 trials
87.5%
+1.0% vs industry average
29%
18 trials in Phase 3/4
43%
21 of 49 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (63)
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
Role: lead
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Role: lead
A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin
Role: lead
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects
Role: lead
A Study of Fosmanogepix in Healthy Adult Chinese Subjects
Role: lead
Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age
Role: lead
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
Role: lead
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
Role: lead
Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function
Role: lead
VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers
Role: lead
Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants
Role: lead
VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers
Role: lead
VNRX-5024 Safety and PK in Healthy Adult Volunteers
Role: lead
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
Role: lead
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
Role: lead
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
Role: lead
Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Role: lead
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
Role: lead
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
Role: lead
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
Role: lead